Scarica l'app Stockscreener
23.28
7.03%
1.53
Dopo l'orario di chiusura:
23.28
Precedente Chiudi:
$21.75
Aprire:
$21.58
Volume 24 ore:
144.71K
Relative Volume:
0.89
Capitalizzazione di mercato:
$1.25B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-32.34
EPS:
-0.7198
Flusso di cassa netto:
-
1 W Prestazione:
-4.16%
1M Prestazione:
+1.13%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$21.58
$23.28
Intervallo di 1 settimana:
$21.58
$25.52
Portata 52W:
$14.85
$28.38
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Nome
Seaport Therapeutics Inc
Settore
Industria
Telefono
617-807-4062
Indirizzo
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
23.28 | 1.16B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Borsa (SPTX) Ultime notizie
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6%Should You Buy? - marketbeat.com
HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX) - marketbeat.com
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - biospace.com
Seaport Therapeutics at citigroup’s biopharma back to school summit 2026: platform push - Investing.com Canada
Seaport Therapeutics reports positive phase 1 trial results - Investing.com
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo - TradingView
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com UK
RCSPureTech Health PLCPRTC's SPTX: New Positive Phase 1 GlyphAllo Data - TradingView
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial - marketscreener.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX - marketbeat.com
Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX - marketbeat.com
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX - marketbeat.com
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - BioSpace
Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX - marketbeat.com
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 6.4%Time to Buy? - marketbeat.com
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighHere's Why - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Stifel Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Top Seaport Therapeutics (SPTX) Competitors 2026 - MarketBeat
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
Seaport Therapeutics (SPTX) Institutional Ownership 2026 - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings - MarketBeat
Analysts’ Top NA Picks: Ceribell, Inc. (CBLL), Ethos Technologies Inc. Class A (LIFE) - The Globe and Mail
Seaport Therapeutics (SPTX): Daphne Zohar discloses 5.23M-share, 9.1% beneficial stake - Stock Titan
Seaport Therapeutics (SPTX) insider Steven M. Paul reports 6.3% stake - stocktitan.net
Seaport Therapeutics Reaffirmed at Buy as Clinical Pipeline Advances and $50 Price Target Remains Unchanged - TipRanks
Citi Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
H.C. Wainwright Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Seaport Therapeutics (NASDAQ:SPTX) Given Buy Rating at HC Wainwright - MarketBeat
Seaport Therapeutics, Inc. 2026 Q2 Financials: Forward-Looking Statements, Risks, and Company Highlights - Minichart
Seaport Therapeutics 2Q Research and Development Expenses Were $24.6M >SPTX - Moomoo
Seaport Therapeutics reports Q2 2026 net loss $62.6M, $427.3M cash; advances GlyphAllo and GlyphAgo - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q2 Loss $1.78 a Share - marketscreener.com
Seaport Therapeutics, Inc. 2Q 2026: Revenue $0 Net loss $(62.6)M, EPS $(1.78) — 10-Q Summary - TradingView
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Yahoo Finance
Seaport Therapeutics Inc Azioni (SPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):